Search
GSK-2981278
go.drugbank.com/drugs/DB16319InvestigationalGSK-2981278 is under investigation in clinical trial NCT03004846 (A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis).
Seviprotimut-L
go.drugbank.com/drugs/DB16328InvestigationalSeviprotimut-L is under investigation in clinical trial NCT01546571 (Study of a Melanoma Vaccine in Stage Iib, Iic, and III Melanoma Patients).
Vixarelimab
go.drugbank.com/drugs/DB16350InvestigationalVixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).
Vonlerolizumab
go.drugbank.com/drugs/DB16352InvestigationalVonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic
BGB-DXP593
go.drugbank.com/drugs/DB16357InvestigationalBGB-DXP593 is a SARS-CoV-2 neutralizing antibody.
Autologous peripheral blood-derived CD34+ cells
go.drugbank.com/drugs/DB16367ApprovedInvestigationalAutologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. … [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).
Matrix-M
go.drugbank.com/drugs/DB16369InvestigationalMatrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.
Astegolimab
go.drugbank.com/drugs/DB16386InvestigationalAstegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Pidacmeran
go.drugbank.com/drugs/DB16401InvestigationalPidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
GRAd-COV2
go.drugbank.com/drugs/DB16428InvestigationalGRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423]. … This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2)[L30420, L30423].